CRIPTO and cancer: In this regard, primary heterotypic organoid cultures, stromally modified patient derived in vitro models and ‘organ on a chip’ approaches hold promise for deconvoluting CRIPTO function with relevant and interpretable yet sophisticated heterotypic signaling cells, key stromal effectors and tumor relevant modified environments that include cancer relevant stresses.